Nasonex (Mometasone Furoate)

Mometasone furoate is a glucocorticoid receptor agonist. After binding to intracellular receptors, it alters gene transcription, decreasing the production of inflammatory cytokines and chemokines in the nasal mucosa, which reduces swelling and irritation.

The dose of Nasonex is individualized by the prescribing clinician based on the patient’s age, condition severity and response to therapy. Patients should follow the specific instructions provided on the prescription label.

Safety data for mometasone furoate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare professional before using Nasonex.

To request Nasonex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Nasonex (mometasone furoate) and fluticasone are potent nasal corticosteroids with similar efficacy for allergic rhinitis. Mometasone has a slightly higher receptor affinity, which may allow effective symptom control at lower doses, but clinical choice often depends on patient preference, device type and prescriber experience.

Nasonex should be stored at room temperature, below 25 °C, in its original packaging. Protect the spray from moisture and direct heat. Keep the device upright and avoid freezing. If the product appears discolored or the spray mechanism is damaged, discard it.

Nasonex is administered as a nasal spray. The recommended technique is to gently blow the nose, insert the tip into one nostril, close the opposite nostril, and spray while breathing in gently. The process is repeated in the other nostril as directed by the prescriber.

Serious risks, though uncommon, include adrenal suppression, severe allergic reactions such as anaphylaxis, nasal septal perforation and opportunistic fungal infections. Patients should seek immediate medical attention if they experience unusual bruising, persistent nosebleeds, visual changes or signs of a severe allergic response.

Nasonex should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal passages and in children under the age approved for the specific product.